Targeted metabolomics reveals tricarboxylic acid cycle-related metabolites serve as predictive biomarkers for trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Journal of molecular medicine

• Publication date

  2025-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00109-025-02603-3PMID 41212217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2023

  2023cited by this paper
• Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.

  2022cited by this paper
• O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1

  2022cited by this paper
• Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers

  2021cited by this paper
• Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness

  2020cited by this paper
• Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

  2020cited by this paper
• Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.

  2020cited by this paper
• Liquid chromatography-mass spectrometry based tissue metabolic profiling reveals major metabolic pathway alterations and potential biomarkers of lung cancer.

  2020cited by this paper
• Cancer biomarker discovery and translation: proteomics and beyond

  2019cited by this paper
• Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

  2019cited by this paper
• UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells

  2019cited by this paper
• Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine

  2018cited by this paper
• Exposure to high levels of fumarate and succinate leads to apoptotic cytotoxicity and altered global DNA methylation profiles in vitro.

  2017cited by this paper
• The emerging role and targetability of the TCA cycle in cancer metabolism

  2017cited by this paper
• Development of a LC-MS/MS Method for the Simultaneous Detection of Tricarboxylic Acid Cycle Intermediates in a Range of Biological Matrices

  2017cited by this paper
• Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition

  2016cited by this paper
• Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer

  2015cited by this paper
• Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes*

  2015cited by this paper
• Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism

  2014cited by this paper
• Quantitative Measurement of Organic Acids in Tissues from Gastric Cancer Patients Indicates Increased Glucose Metabolism in Gastric Cancer

  2014cited by this paper
• Proteomics: improving biomarker translation to modern medicine?

  2013cited by this paper
• Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

  2010cited by this paper
• Glutamine addiction: a new therapeutic target in cancer.

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009influential reference
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Her2-positive breast cancer: herceptin and beyond.

  2008cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.

  2006cited by this paper
• Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response.

  2006cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005cited by this paper
• Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

  2002cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• No citing papers are available for this paper.